BioXcel Therapeutics (NASDAQ:BTAI) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

BioXcel Therapeutics (NASDAQ:BTAI) announced its quarterly earnings results on Thursday. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05), FiscalAI reports. The company had revenue of $0.18 million for the quarter, compared to analysts’ expectations of $0.48 million.

BioXcel Therapeutics Price Performance

BTAI stock opened at $1.13 on Friday. The company has a market cap of $34.89 million, a price-to-earnings ratio of -0.20 and a beta of 0.31. The company has a fifty day moving average price of $1.04 and a 200 day moving average price of $1.25. BioXcel Therapeutics has a 12 month low of $0.74 and a 12 month high of $6.85.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on BTAI shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Friday, July 17th. Wall Street Zen downgraded BioXcel Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $11.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BTAI. Millennium Management LLC boosted its stake in shares of BioXcel Therapeutics by 78.5% during the fourth quarter. Millennium Management LLC now owns 1,835,192 shares of the company’s stock worth $2,936,000 after buying an additional 807,139 shares during the period. State Street Corp grew its holdings in shares of BioXcel Therapeutics by 19.9% during the fourth quarter. State Street Corp now owns 63,218 shares of the company’s stock worth $101,000 after buying an additional 10,500 shares during the last quarter. Jane Street Group LLC acquired a new position in BioXcel Therapeutics in the 4th quarter valued at about $204,000. Geode Capital Management LLC increased its position in BioXcel Therapeutics by 64.6% in the 4th quarter. Geode Capital Management LLC now owns 206,168 shares of the company’s stock valued at $330,000 after acquiring an additional 80,928 shares during the period. Finally, Man Group plc purchased a new stake in BioXcel Therapeutics during the 4th quarter valued at approximately $91,000. 30.68% of the stock is currently owned by institutional investors and hedge funds.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.